We are live on ! Find out more
VYNE icon

VYNE Therapeutics
VYNE

56 hedge funds and large institutions have $68.4M invested in VYNE Therapeutics in 2018 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 17 increasing their positions, 14 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

36% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 11

21% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 14

8% more funds holding

Funds holding: 52 → 56 (+4)

0.01% more ownership

Funds ownership: 0.99% → 0.99% (+0.01%)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

57% less capital invested

Capital invested by funds: $161M → $68.4M (-$92.3M)

Holders
56
Holders Change
+4
Holders Change %
+7.69%
% of All Funds
1.25%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
15
Increased
17
Reduced
14
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
GPP
Great Point Partners
Connecticut
+$5.6M
2
First Manhattan
First Manhattan
New York
+$2.35M
3
DCM
DAFNA Capital Management
California
+$1.42M
4
AIM
Alambic Investment Management
California
+$1.07M
5
JP Morgan Chase
JP Morgan Chase
New York
+$736K

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$4.66M
2
RSCM
Rock Springs Capital Management
Maryland
-$3.25M
3
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$2.6M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$1.87M
5
NHAS
Novo Holdings A/S
Denmark
-$1.04M
Name Holding Trade Value Shares
Change 		Change in
Stake
PNC Financial Services Group
51
PNC Financial Services Group
Pennsylvania
$2K – – –
BNP Paribas Financial Markets
52
BNP Paribas Financial Markets
France
$1.57K +$895 +2 +67%
Barclays
53
Barclays
United Kingdom
$1K -$21.9K -49 -92%
Royal Bank of Canada
54
Royal Bank of Canada
Ontario, Canada
$1K -$2.69K -6 -67%
Bank of Montreal
55
Bank of Montreal
Ontario, Canada
$1K +$448 +1 +100%
Fidelity Investments
56
Fidelity Investments
Massachusetts
$1K +$2.24K +5 New
O
57
OrbiMed
New York
– -$4.66M -6,566 Closed
RSCM
58
Rock Springs Capital Management
Maryland
– -$3.25M -4,583 Closed
SSA
59
Schonfeld Strategic Advisors
New York
– -$493K -694 Closed
BFM
60
Boothbay Fund Management
New York
– -$315K -444 Closed
TCM
61
Tekla Capital Management
Massachusetts
– -$244K -344 Closed
TCIM
62
TIAA CREF Investment Management
New York
– -$184K -259 Closed
ARTA
63
A.R.T. Advisors
New York
– -$179K -253 Closed
TI
64
Trexquant Investment
Connecticut
– -$151K -214 Closed
VF
65
Virtu Financial
New York
– -$126K -178 Closed
PSC
66
Piper Sandler & Co
Minnesota
– -$5.37K -12 Closed
PCM
67
Prelude Capital Management
New York
– -$1K -1 Closed
1 2
3

VYNE Hedge Fund Activity: Q4 2018 in Review

56 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in VYNE Therapeutics (VYNE) for Q4 2018, worth a combined $68.4M — down 57% from $161M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new VYNE positions and 11 closed out — a net gain of 4 holders — while 17 added to existing stakes and 14 trimmed.

The largest buyer was Great Point Partners, adding an estimated $5.6M. The largest seller was OrbiMed, exiting entirely with an estimated $4.66M sold.

  • 56 institutional investors held VYNE Therapeutics (VYNE) as of Q4 2018, up from 52 in Q3 2018.
  • Funds reported $68.4M of VYNE Therapeutics stock for Q4 2018, down 57% quarter-over-quarter.
  • 15 funds opened new VYNE Therapeutics positions in Q4 2018 and 11 closed out, a net change of +4 holders.
  • The largest VYNE Therapeutics buyer in Q4 2018 was Great Point Partners, an estimated $5.6M added.
  • The largest VYNE Therapeutics seller in Q4 2018 was OrbiMed, an estimated $4.66M sold.

Based on aggregated 13F filings for Q4 2018.